Statement of Work.pdf

STATEMENT OF WORK

1. GENERAL INFORMATION

1.1. Title of Project: Reference Laboratory Testing Services for Amarillo VA Health Care System

1.2. Background: The Amarillo VA Health Care System (AVAHCS) and affiliated sites including associated Community Based Outpatient Clinics (CBOC) and Health Clinics require referral laboratory services for diagnostic testing not performed in house. These services are essential for ensuring timely diagnosis, continuity of care, and compliance with evidence-based clinical standards. AVAHCS serves a geographically dispersed Veteran population, including rural and remote communities, making access to comprehensive and reliable diagnostic testing a critical operational need. A formal reference laboratory contract is necessary to ensure continuity, reliability, and regulatory compliance in meeting these clinical demands through a structured, accredited, and performance-monitored partnership.

1.3. Scope of Work: This full-service reference laboratory contract will provide services required for specimen testing, interpretation, testing supplies, courier, customer service, system interfaced lab result reporting services and verification of certification for test results. Services shall include analytical testing & results reporting for clinical, anatomical, and cytological modalities for any/all sample types, including but not limited to blood, urine, tissue, and other body fluids and will include courier services for specimen transportation from AVAHCS sites to reference laboratory as needed. This requirement will ensure accurate and timely test results are made available to the AVAHCS healthcare providers to deliver high-quality healthcare to AVAHCS Veterans.

This contract will support any test currently offered by the contractor or its subcontractor labs within their network. Due to the clinical unpredictability and diversity of test needs, it is not feasible to list every individual test. Instead, the contractor shall provide access to its full test menu, including newly developed or updated tests, without the need for amendment. Services include test performance, reporting, consultation, supply provision, and maintenance of local patient service centers (PSCs) in Amarillo, Lubbock, and Clovis to support Veteran specimen collection in the event VA phlebotomy services are unavailable or disrupted at any of the primary locations.

Test results must be returned via secure interface, with the contractor completing interface implementation within 60 days of contract award.

1.4. Performance Period:

1.4.1. January 1, 2026 – December 31, 2026 (Base Year), with four one-year options (through December 31, 2030).

1.5. Type of Contract:

1.5.1. Indefinite Delivery, Indefinite Quantity (IDIQ) with quantities and specific tests ordered as needed. Attachment A has a list of estimated monthly test volumes. This list isn’t all inclusive list of needed tests. The need is for any test currently offered by the contractor or its subcontractor labs within their network.

1.6. Places of Performance:

1.6.1. Thomas E. Creek VA Medical Center: 6010 Amarillo Blvd W, Amarillo, TX 79106

1.6.2. Lubbock VA Community Based Outpatient Clinic: 3510 4th St, Lubbock, TX 79415

1.6.3. Childress VA Clinic: 2305 Avenue F Northwest, Suite 900 Childress, TX 79201-2113

1.6.4. Clovis VA Clinic: 921 East Llano Estacado Boulevard Clovis, NM 88101-3807

1.6.5. Dalhart VA Clinic: 325 Denver Avenue Dalhart, TX 79022-2711

2. REQUIREMENTS:

2.1. Specific Tasks

2.1.1. The Reference Laboratory shall provide in accordance with all applicable federal, state, and local regulations, laws, and ordinances, and in accordance with the specifications outlined for accreditation certification if applicable, patient specimen testing for the specific range of referral testing within their capability.

2.1.2. Services shall include the performance of analytical testing as defined by the Laboratory's reference test manual, the reporting of analytical test results and consultative services as required.

2.1.3. All requirements and provisions defined in the specifications of this solicitation will apply to any laboratory, i.e., branch, division, sub-contractor, etc. performing reference testing on behalf of the Reference Laboratory.

2.1.4. Generally, the AVAHCS facilities will be responsible for specimen collection and will provide laboratory specimens prepared according to the Reference Laboratory's user’s manual, identified, and labeled for testing.

2.1.5. Provision local patient service centers (PSCs) in Amarillo TX, Lubbock TX, and Clovis NM to support Veteran specimen collection in the event VA phlebotomy services are unavailable or disrupted at any of the primary locations.

2.1.6. Reference Laboratory must be capable of arranging daily specimen pickup at all AVAHCS affiliated hospitals and clinics (listed in section 1.6).

2.1.7. Reference Laboratory shall provide laboratory services to include pre-analytic processing as defined in Reference Laboratory published user’s manual, analysis, reporting of analytic results and interpretation of analytic clinical results. The number of tests requested under this contract will change throughout the life of the contract. The volumes or amounts shown in the solicitation are estimates only and impose no obligation on the

VA.

2.1.8. The Reference Laboratory shall also provide the following support services: supplies, customer service, reporting services, courier and verification of certification.

2.1.9. Provide all necessary supplies as defined in the laboratory user manual, to include, but not limited to the following:

2.1.9.1. Requisition forms or agreed computer ordering system.

2.1.9.2. Specimen containers & collection kits.

2.1.9.3. Specimen requirements for specimen collection & specimen processing.

2.1.9.4. Methodologies and reference ranges.

2.1.9.5. Expected turn-around times.

2.1.9.6. All forms, including authorization of consent for genetic testing, informed consent, and chain of custody.

2.1.10. The Reference Laboratory shall provide to the VA Facilities the supplies and equipment within one (1) week of receipt of the delivery order. The VA Facilities will request replenishment of supplies from the Reference Laboratory on an as needed basis via telephone or fax. A confirmation of the order shall be supplied to the VA within 24 hours.

2.1.11. All supplies shall be shipped by contractor to AVAHCS and/or to AVAHCS affiliated facility.

2.2. Electronic Interface

2.2.1. If awarded the Reference Laboratory agrees to a transition period for providing a fully functioning interconnection for exchanging data between our current system “VISTA “to the Reference Laboratory's electronic lab information system. During this time the Reference Laboratory will supply the VA Facility with available test menu and agrees to receive test orders. The Reference laboratory agrees to work with VISTA system to ensure connectivity and aid the VA. Test orders that were created for testing the interface system will be at no charge.

2.2.2. Vendors shall have solidified VISTA electronic test list ready to go for AVAHCS to be used upon 1/1 (PoP start) and data transfer ready to be used upon start of POP 1/1.

2.2.3. System drivers must be compatible with the VA’s VISTA system. The server and interface software will be owned and maintained by the Reference Laboratory. The Reference Laboratory must have a signed MOU (Memorandum of Understanding) with the VA Network and Security Operations Center (NSOC).

2.2.4. This interconnection shall be protected using VA approved encryption algorithms and products as required and in compliance with HIPAA guidelines. Connections at each end shall be located within a controlled access facility. All access shall be controlled by authentication methods to validate approved users.

2.2.5. Reference Laboratory shall notify VA Facilities of any specimen problems or discrepancies from the submitted manifest within 24 hours after shipping.

2.3. Testing Methodology, Reference and Turn Around Time

2.3.1. Routine test results shall be reported within the specified turnaround time (TAT) which is defined from time of specimen receipt by the contractor to when results are available. If testing is going to be delayed and the results will not be within published TAT, notify the VA Facilities of the new estimated TAT within 12 hours.

2.3.2. Testing methodology and reference ranges for a test must be defined in the Reference Laboratory user manual and/or website. Reference Laboratory shall advise facility of any changes in methodology, procedure, reference ranges and any new tests introduced 30 days in advance.

2.3.3. Reference Laboratory agrees to maintain the minimum acceptable service, reporting systems and quality control. Exception handling: Reference Laboratory will notify VA Facilities Laboratory Service within 12 hours of any problems with specimens received.

2.3.4. The VA Facilities will provide laboratory specimens prepared according to the Reference Laboratory's user’s manual, identified, and labeled for testing.

2.3.5. Critical Value test results shall be reported immediately. Telephoned results will be confirmed with a follow-up by vendor via fax.

2.3.6. The Reference Laboratory shall provide in accordance with all applicable federal, state, and local regulations, laws, and ordinances, and in accordance with the specifications outlined for accreditation certification if applicable, patient specimen testing. All requirements and provisions defined in the specification of this solicitation will apply to any laboratory, i.e. branch, division, sub-contractor, etc. performing reference testing on behalf of the Reference Laboratory.

2.3.7. Operate a dedicated, temperature-controlled courier fleet for specimen pickups.

2.4. Customer Service & Patient Information Safety

2.4.1. The reference laboratory will provide VA Laboratory with a means of communication to permit immediate inquiry regarding the status of pending tests or specimen problem, 24 hours per day, 7 days per week.

2.4.2. The reference laboratory shall provide names and telephone numbers of Technical Directors and Pathologists available to provide information.

2.4.3. Reference lab agrees not to use or disclose Protected Health Information (PHI) other than as permitted or required by the agreement or as required by law.

2.4.4. Reference lab agrees to use appropriate safeguards to prevent use or disclosure of the PHI other than is provided for by this agreement.

2.4.5. Reference lab agrees to report immediately any breach of safeguards and to mitigate any harmful effect related to the use or disclosure of PHI by the Reference Laboratory or any of its agents, including subcontractors.

2.4.6. The reference lab will comply with reporting test results with the specified time frame in accordance with the nature of the testing, following all regulatory requirements for reporting of patient results. Test results shall be reported within specified times established by the reference laboratory. Critical value test results shall be reported immediately by telephone. Results will be sent to the VA via a secure means and in compliance with Health Portability and Accountability Act (HIPPA) guidelines.

2.4.7. The contractor will provide test related information that is readily available and easy to access to help select the proper test, interpret results, and build tests in VISTA for interconnection for electronic data interchange (EDI).

2.4.8. The contractor will provide a 24-hour response time to all inquiries made by P&LMS.

2.4.9. The Reference Laboratory courier shall be responsible for transporting and storing specimens in such a manner as to ensure integrity of the specimen where applicable and protect patient sensitive information.

2.4.10. The Reference Laboratory shall provide routine scheduled specimen pickup at a time mutually agreed upon by the AVAHCS facilities. Specimens will be picked up daily and weekends, if needed, at no extra charge to the government.

2.5. Delivery and Reporting

2.5.1. Billing summaries shall begin the first day of the month and include the last day of the month.

2.5.2. Tests referred to another laboratory shall be at no additional transfer charge or confirmation charge to the government.

2.5.3. Deliveries must be accompanied by a delivery ticker or sales slip that contains the following information as a minimum:

2.5.3.1. Vendor Name

2.5.3.2. Applicable FSS contract number

2.5.3.3. BPA Number, Task order number, and Purchase Order number

2.5.3.4. Date of Purchase

2.5.3.5. Date of Shipment

2.5.3.6. Description of item

2.5.3.7. Quantity of each item

2.5.3.8. Unit price and extended (quantity x unit price) price for each item

2.5.4. The Reference Laboratory shall provide a quarterly and end of year report showing sample issues, facility usage, and cost savings generated during the reporting period. The report will be due 45 days after the close of each government fiscal quarter.

2.6. **NOTE: See Section 'Contract Restrictions' regarding marketing limitations.**

3. PERFORMANCE MONITORING

3.1. To minimize administrative burden, the following performance standards will be used for tracking, based on easily accessible documentation such as invoices, email logs, supply confirmations, and scheduled reports. The Contractor shall be subject to the following standards and acceptable quality levels (AQL):

3.1.1. Standard 1 – Invoice Accuracy: Monthly invoices must reflect accurate CPT codes, units, and test names. Acceptable Quality Level (AQL): 95%

3.1.2. Standard 2 – Critical Result Notification: Panic values must be reported verbally to

AVAHCS within 1 hour of result verification, followed by written confirmation. AQL: 100%

3.1.3. Standard 3 – Customer Service Response Time: All test-related inquiries must be addressed within 24 business hours. AQL: 100%

3.1.4. Standard 4 – Supply Delivery: Requested supplies must be confirmed within 24 hours and delivered within 7 calendar days. AQL: 95%

3.1.5. Standard 5 – Quarterly Report Submission: Usage and issue reports must be submitted within 45 days of each fiscal quarter's close. AQL: 95%

4. LICENSING AND ACCREDITATION

4.1. Reference Laboratory shall provide copies of all licenses, permits, accreditation and certificates required by law. Laboratory Director shall be a licensed American Board of Pathology certified pathologist or appropriately certified bio-analyst.

4.2. All medical facilities providing laboratory services under the contract must possess a valid state license and meet JC standards as well as CLIA requirements and standards of the College of American Pathologists (CAP).

4.3. The Reference Laboratory shall make sure employees have current and valid professional certifications before starting work under this contract.

4.4. The Reference Laboratory staff shall meet personnel qualifications required by Clinical Laboratory

Improvement Act (CLIA) '88 Guidelines. Contractor shall participate in proficiency testing (PT) programs such as CAP or equivalent and provide PT performance summaries and quality control documentation upon request by the COR or designated government representative.

4.5. The Government’s reserves the right to request information or certification from the contractor verifying they comply with this contract requirement. If discovered the contractor is not in compliance with this requirement the contract shall be terminated for cause in accordance with clause 52.212-4.

5. WORK SITE ACCESS

5.1. Coordinate access with the COR during normal hours (8:00 AM – 4:30 PM, Monday–Friday, excluding federal holidays).

5.2. Afterhours access will be permitted as deemed necessary by both the Vendor or the COR and/or or laboratorian.

5.3. Comply with VA security protocols, including background checks and ID verification for personnel, if necessary.

6. EXECUTION

6.1. Perform all work in a safe and efficient manner per OSHA (29 CFR 1910.1030), FDA, and AABB safety guidelines, or other applicable standards.

6.2. Optimize delivery/pickup schedules to minimize disruption, prioritizing STAT requests.

6.3. Designate a 24/7 POC for COR communication and conduct weekly status meetings (virtual or in-person).

7. SECURITY

7.1. The contractor, their personnel, and their subcontractors shall be subject to the Federal laws, regulations, standards, and VA Directives and Handbooks regarding information and information system security as delineated in this contract.

7.2. Comply with VA security protocols, including background checks and ID verification.

7.3. The C&A requirements do not apply, and that a Security Accreditation Package is not required.

7.4. Secure patient data per HIPAA and VA Directive 6500, with no Certification and Accreditation

(C&A) required.

7.5. Ensure tamper-proof handling and transportation with chain-of-custody documentation.

8. BILLING AND INVOICING

8.1. Monthly billing and test report summaries shall begin on the first day of the month and include the last day of the month.

8.2. VA-FSC shall require the following information in compliance with the Prompt Pay Act and Business Requirements.

8.2.1. Your Taxpayer ID number (TIN)

8.2.2. Your “Remit Address” information

8.2.3. The VA Purchase Order (PO) number

8.2.4. Your contact information: (Personal name, Email, and Phone)

8.2.5. Your VA Point of contact information (Personal name, Email, and Phone)

8.2.6. The Period of Performance dates (POP Beginning and Ending)

8.2.7. All discount information if applicable (Percent and Date Terms)

8.2.8. Reagents used with pricing per unit

8.2.9. No freight charges to be added to the invoice

8.3. Department of Veterans Affairs Financial Service Center:

8.3.1. Phone:1-877-353-9791

8.3.2. Email: vafscched@va.gov

8.4. AVAHCS shall not be responsible for payment of services and or supplies which were not requested in accordance with the contract.

8.5. AVAHCS will NOT pay for tests that are not clearly identified by product number on the invoice.

8.6. Invoices are to be separate for Amarillo and Lubbock laboratories, but the usage of the same PO number is acceptable for billing purposes.

8.7. Invoices will be electronically submitted to the Tungsten website at:

8.7.1. http://ww.tungsten-network.com/uk/en/

8.7.2. Tungsten direct vendor support number is 877-489-6135 for VA contracts.

8.8. All invoices submitted through Tungsten to VA-FSC should mirror your current submission of

Invoice.

ATTACHMENT A: AMARILLO VA HEALTH CARE SYSTEM MONTHLY TEST VOLUME ESTIMATES

(Note: Total monthly estimated test volume is across all sites) mailto:vafscched@va.gov http://ww.tungsten-network.com/uk/en/

TEST DESCRIPTION TOTAL TEST COUNT

( 28 MONTHS: JAN 2023 - APR 2025)

MONTHLY ESTIMATE

(ROUNDED UP)

**ADULT FOOD ALLERGY PROF 7 1

**ALCOHOL METAB, QN, U 8 1

**DM BARBITURATES QN U 1 1

**DM BENZO QN U 19 1

**DM BUP AND NAL QN, U 1 1

**DM COCAINE MET QN U 9 1

**DM FENTANYL,QN,U 2 1

**DM MARIJUANA M QN U 60 3

**DM METHAMP ISOMERS,U 3 1

**DM MPHENIDATE M,QN,U 34 2

**DM OPI EXPANDED QN U 2 1

**DM OXYCODONE QN U 4 1

**DM ZOLPIDEM QN, UR 1 1

**GEN TOX LC/MS/MS, U 1 1

**HLA-A29 TYPING 1 1

**HLA-B51 TYPING 1 1

**HSV1/2 IGM,W/RFL CSF 1 1

**KAPPA/LAMBDA 24 HR U 1 1

**KAPPA/LAMBDA QT 3 1

**MYOGLOBIN, (U) 10 1

**PHARMACOGENOMICS PANEL 1 1

**PNEUMO AB PANEL 14 2 1

**VIP 2 1

14 3 3 ETA PROTEIN 1 1

14-3-3 PROTEIN,CSF 1 1

17-OHPROGEST.LC/MSMS 7 1

21-HYDROXYLASE AB 1 1

3A ANDRO GLUCURONIDE 1 1

5 HIAA,24 HR W/CREAT 9 1

A-1-ANTITRYPSIN QN 35 2

ABL MUTATION 2 1

ACHR BINDING AB 80 3

ACHR BLOCKING 60 3

ACHR MODULATING AB 78 3

ACTH 116 5

ACTIN ANTIBODY (IGG) 2 1

ACYLCARNITINE PLASMA 2 1

ACYLGLYCINES IN UR 1 1

ADALIMUMAB ADA IBD 1 1

ADALIMUMAB LEVEL IBD 1 1

ADAMTS13 ACTIV.W/RFL 5 1

ADENOSINE DEAMINASE, PLEU 5 1

ADIPONECTIN 1 1

AEROBIC BACTERIA ID & S 10 1

ALBUMIN 314 12

ALDOLASE 120 5

ALDOSTERONE (U) 8 1

ALDOSTERONE,LC/MS 195 7

ALK PHOS ISOENZYMES 41 2

ALLERGY 2, SE 2 1

ALPHA 3 AB 20 1

ALPHA SUBUNIT 3 1

ALPHA THAL MUT ANAL 10 1

MONTHLY ESTIMATE

(ROUNDED UP)

ALT 5 1

ALUMINUM, BLOOD 3 1

AMH, FEMALE 1 1

AMINO ACID FRAC, P 1 1

AMIODARONE 12 1

AMITRIPTYLINE 1 1

AMPHETAMINE QN,SERUM 5 1

AMPHETAMINES,QN,U 13 1

ANA TITER&PATTERN 19 1

ANA W/RFX 49 2

ANAEROBIC BACT. ID 11 1

ANAEROBIC ID& SUSCEP 1 1

ANCA SC W/RFL TITER 275 10

ANGIOTENSIN CONV ENZ 151 6

ANTI-DSDNA AB, EIA 173 7

ANTI-GM1 33 2

ANTI-HU AB,WB 1 1

ANTI-HU RFX/TITER/WB 1 1

ANTITHROMBIN III ACT 67 3

ANTITHROMBIN III AG 19 1

APC RESISTANCE 4 1

APOE ISOFORM, PLASMA 6 1

APOLIPOPROTEIN B 6 1

APOLIPOPROTEIN EVAL 24 1

AQP4 (NMO IGG) 16 1

AQUAPORIN 4 AB, CBA 1 1

ARSENIC (B) 72 3

ARSENIC (U) 1 1

ASP FUMIGATUS IGG AB 5 1

ASPERGILLUS ANTIGEN 9 1

AST 5 1

ATAXIA,COMP EVAL 1 1

ATYP P-ANCA TITER 14 1

B.HENSELAE IGG SCR 2 1

B.HENSELAE IGM SCR 2 1

B2-GLYCO I(IGA) 224 8

B2-GLYCO I(IGG) 224 8

B2-GLYCO I(IGM) 224 8

BCR ABL1 GENE QN PCR 21 1

BERYLLIUM;B 1 1

BETA-2-MICROGLOBULIN 179 7

BETA-GLOBIN COMPLETE (TM) 2 1

BICARBONATE;U 1 1

BILIRUBIN,BODY FLUID 7 1

BK VIRUS DNA,QN,PCR 8 1

BKV PCR, QUANT 57 3

BLADDER CANCER, FISH 1 1

BLASTOMYCES AB, ID 3 1

BP180 1 1

BRCA PANEL PLUS 1 1

BRCA(TM), COMP 1 1

BRUCELLA IGG,IGM 6 1

BULLOUS PEMPHIGOID 1 1

MONTHLY ESTIMATE

(ROUNDED UP)

BUPRENORPHINE SERUM 7 1

C DIFF TOXIN W/REFL 10 1

C-ANCA TITER 1 1

C-PEPTIDE 152 6

C1 INHIBITOR, FUNCT 7 1

C1 INHIBITOR, PROTEIN 4 1

CA 15-3 13 1

CA 19-9 (CENTOCOR) 86 4

CA125 27 1

CA27.29 CHIRON/BAYER 18 1

CADMIUM (B) 2 1

CALCITONIN 13 1

CALCIUM, IONIZED 29 2

CALPROTECTIN,STOOL 122 5

CALR MUTATION 30 2

CAMPY CULTURE 1 1

CAMPYLOBACTER,ELISA 2 1

CARBOXYHEMOGLOBIN 2 1

CARDIOLIPIN IGA AB 216 8

CARDIOLIPIN IGG AB 221 8

CARDIOLIPIN IGM AB 218 8

CARDIOLP AB G/M/A 15 1

CARNITINE, LC/MS/MS 4 1

CAROTENE 2 1

CATECHOLAMINES 24HR 47 2

CATECHOLAMINES,PLASM 24 1

CCP AB IGG 383 14

CENTROMERE AB, EIA 7 1

CERULOPLASMIN 29 2

CHICKEN MEAT IGG 1 1

CHLAMYDIA PNEU.PNL 2 1

CHOLESTEROL,PLEUR.FL 5 1

CHROMIUM, BLOOD 1 1

CHROMOGRANIN A 25 1

CHROMOSOME, BLOOD 2 1

CITRIC ACID 24HR (U) 3 1

CK ISOENZYMES 21 1

CK, TOTAL 25 1

CLOSTRIDIUM DIF TBR QL 3 1

CMV DNA QN, PCR 16 1

CMV IGG AB 106 4

CMV IGM AB 106 4

COAG FACTOR IX ACT 2 1

COAG FACTOR V ACT 12 1

COBALT, S/P 1 1

COCCI AB TO TP/F AG 2 1

COCCIDIO AB, ID 11 1

COCCIDIOIDES AB, CF 11 1

COENZYME Q10 1 1

COLD HEMAGGLUTININS 2 1

COLLAGEN TYPE I CTX 22 1

COMP C3C4 2 1

COMPLEMENT C3C 1 1

MONTHLY ESTIMATE

(ROUNDED UP)

COMPLEMENT C4C 1 1

COMPLEMENT COMP C1Q 3 1

COMPLEMENT, (CH50) 2 1

COPEPTIN 2 1

COPPER 104 4

CORTISOL, FREE 1 1

CORTISOL, FREE 24HR 37 2

CORTISOL,SALIVA 4 1

COXSACKIE A AB 1 1

COXSACKIE B VIRUS AB 1 1

CREATININE (U) 65 3

CREATININE RAND (U) 11 1

CRYOGLOB (REFL) 1 1

CRYOGLOB EVAL 21 1

CRYOGLOBULIN,%CRYO 27 1

CRYP.AG L.A. W/TITER 10 1

CULT,FUN,SKIN,W/SMR 13 1

CULT,FUNGUS,OTHER 18 1

CULTURE FUNGUS BLOOD 1 1

CULTURE FUNGUS S/H/N 6 1

CULTURE, VIRUS 2 1

CYCLOSP TR FPIA 9 1

CYP2D6 1 1

CYSTATIN C W/EGFR 1661 60

DENGUE FEVER IGG 3 1

DENGUE FEVER IGM 3 1

DESMOGLEIN AB 1 1

DEXAMETHASONE 3 1

DHEA, LC/MS/MS 8 1

DHEA-SULFATE 30 2

DIHYDROTESTOSTERONE 1 1

DIPHTHERIA ANTITOXOID 3 1

DIRECT LDL 9 1

DM,PHOSPHATIDYELTH,B 27 1

DONOR HTLV I/II 5 1

DONOR,HIV 1/HBV/HCV 2 1

DRUG ABUSE PANEL 8, W CON 14 1

DRVVT 1:1 MIX 11 1

DRVVT CONFIRM 77 3

DRVVT W/RFL PHOS.NEU 215 8

EBV AB PANEL 32 2

EBV DNA QT. PCR 18 1

EHRLICHIA CHAF AB 3 1

ELASTASE EL1, STOOL 14 1

ELECTROLYTES (FECES) 9 1

ENDOMYSIAL IGA AB 9 1

ERYTHROCYTE PORPHY 3 1

ERYTHROPOIETIN 189 7

ESTRADIOL 268 10

ESTRADIOL,EXTRACTION 18 1

ESTRIOL,SERUM 13 1

ESTROGEN, TOTAL (S) 82 3

ESTRONE 13 1

MONTHLY ESTIMATE

(ROUNDED UP)

FACTOR II ACTIVITY 20 1

FACTOR V (LEIDEN) 101 4

FACTOR VII ACTIVITY 6 1

FACTOR VIII ACT CLOT 24 1

FACTOR X ACTIVITY 7 1

FACTOR X CHROMOGENIC 1 1

FACTOR XI ACTIVITY 4 1

FACTOR XII ACTIVITY 2 1

FECAL FAT, QUAL 46 2

FECAL LIPIDS, TOTAL 3 1

FENTANYL NORFENTANYL 7 1

FIBRIN SPLIT PROD QN 1 1

FISH CML/ALL BCR/ABL 12 1

FISH IGH/CCND1 2 1

FISH,B-CELL CLL PNL 10 1

FLECAINIDE 2 1

FOLATE, RBC 154 6

FRUCTOSAMINE 52 2

FUNGAL ID, MOLDS 5 1

FUNGAL ISOLATE ID 11 1

FUNGITELL(1-3)B-D-GL 5 1

G-6-PD (B) 30 2

GABAPENTIN, PLASMA 1 1

GAD-65 AB 84 3

GAD65 AB ASSAY, CSF 1 1

GAST,PARIETAL CELL AB 1 1

GASTRIN 2 1

GBM ANTIBODY 23 1

GLIADIN AB IGG 1 1

GLUCAGON 1 1

GLUTEN IGG 3 1

HANTAVIRUS AB,ELISA 3 1

HAPTOGLOBIN 129 5

HBSAG CONFIRMATION 2 1

HBV DNA QUANT 53 2

HCG, TOTAL, QN 36 2

HCV GENOTYPE LIPA(R) 41 2

HCV RNA BY PCR,QT 32 2

HDL SUBCLASSES 3 1

HEMOGLOBINOPATHY 38 2

HEMOSIDERIN STAIN 1 1

HEP A AB, TOTAL 289 11

HEP A AB,W/REFL IGM 1 1

HEP A IGM AB 22 1

HEP B CORE IGM AB 35 2

HEP B SURF AG W/CONF 32 2

HEP BE AB 41 2

HEP BE AG 41 2

HEP DELTA VIRUS AB 11 1

HEP INDUCED PLAT AB 7 1

HEPARIN, ANTI XA 6 1

HEREDITARY HEMO 56 2

HERPES VIRUS8 DNA QN 2 1

MONTHLY ESTIMATE

(ROUNDED UP)

HEXAGONAL PHASE CONF 2 1

HGB INDICES 38 2

HGH 11 1

HHV 6 DNA,QL RT-PCR 1 1

HIAA, 5 (U) 1 1

HIST REL 2 1

HISTOPLASMA AB BY ID 7 1

HISTOPLASMA AB, CF 7 1

HISTOPLASMA GALAC AG 8 1

HIV 1 CORE TROPISM 1 1

HIV 1 RNA, QL RT PCR 11 1

HIV 1/2 AB DIFF W/RF 22 1

HIV-1 RESISTANCE 2 1

HIV-1 RNA,QN,RT PCR 241 9

HIV1 PROVIRAL COREC TROP 3 1

HLA-B*15:02 1 1

HLA-B*5701 TYPING 2 1

HLA-B27 ANTIGEN 291 11

HMGCR AB (IGG) 2 1

HOMOCYSTEINE 1 1

HSV 1 IGG 2 1

HSV 1/2 DNA QN PCR 8 1

HSV 1/2 IGG TYPE SP 267 10

HSV 1/2 W/REFL 8 1

HSV 2 IGG INHIBITION, IA 4 1

HSV CULT 11 1

HSV TYPE 1 & 2, PCR 1 1

HSV2 INHIBITION 2 1

HUNTINGTON'S DISEASE 6 1

HYDROCODONE AND MTB 268 10

HYPER PNEUMO EVAL 1 1

HYPOGLYCEMIC PAN;SP 1 1

IA-2 ANTIBODY 6 1

IGF I, ECL 33 2

IGG SUBCLASS PANEL 69 3

IGG SYNTHESIS/INDEX 8 1

IGVH MUTATION 3 1

IL-6 7 1

IMCAP, CLAM (F207) 1 1

IMCAP, GLUTEN (F79) 2 1

IMMUNOFIX, UR 25 1

IMMUNOFIXATION, SERUM 328 12

IMMUNOGLOBULIN A 261 10

IMMUNOGLOBULIN D 1 1

IMMUNOGLOBULIN E 18 1

IMMUNOGLOBULIN G 239 9

IMMUNOGLOBULIN M 231 9

INCUBATED PTT LA MIX 7 1

INFLIXIMAB ADA IBD 1 1

INFLIXIMAB LEVEL IBD 1 1

INHIBIN B 1 1

INSULIN 145 6

INSULIN ABS, HIGHLY 16 1

MONTHLY ESTIMATE

(ROUNDED UP)

INTERLEUKIN 2 RECP. 2 1

INTRINSIC FACTOR AB 5 1

IODINE SERUM,PLASMA 4 1

ISLET CELL AB TITER 1 1

ISLET CELL RFX TITER 19 1

JAK2 EXON 12 MUTATN 16 1

JAK2 V617F MUTATION 119 5

JC VIRUS DNA QN PCR 36 2

JO-1 ANTIBODY 59 3

KAPPA/LAMBDA (U) 35 2

KAPPA/LAMBDA W/RATIO 249 9

KIT D816 MUT ANAYL 1 1

L PNUEMO IGM 13 1

LACOSAMIDE 11 1

LACTOFERRIN,QL,STOOL 14 1

LAMOTRIGINE 14 1

LD ISOENZYMES 1 1

LD, SYNOVIAL FLUID 1 1

LDH, TOTAL 1 1

LEAD (U) 3 1

LEAD, (B) 89 4

LEGIONELLA CULTURE 71 3

LEISHMANIA AB (IGG) 1 1

LEU & LYM 22 MARKERS 93 4

LEU & LYM 24 MARKERS 3 1

LEU & LYM 25 MARKERS 2 1

LEU & LYMP 26 MARKERS 2 1

LEVETIRACETAM IA 161 6

LIVER CYTOSOLIC IGG 1 1

LIVER FIBROSIS 130 5

LKM-1 ANTIBODY(IGG) 12 1

LUPUS ANTICOAG HEX 24 1

LUPUS ANTICOAG W/RFL 128 5

LYME AB W/REFL BLOT 75 3

LYME DIS IGG/M BLOT 6 1

LYME IGG,WB CSF 3 1

LYME IGM,WB CSF 3 1

LYMPH SUBSET PNL 2 229 9

LYSOZYME, SERUM 3 1

M PNEUMO IGG AB 24 1

M. PNEUM IGM AB 24 1

MAG IGM 33 2

MEASLES AB IGG,EIA 7 1

MEASLES AB IGM, IF 8 1

MERCURY (B) 73 3

METANEPHRINES,FRACT 76 3

METANPH.24 HR URINE 50 2

METANPH.RANDOM URINE 4 1

METHADONE CONFIRMATION SE 8 1

METHOTREXATE 1 1

METHYLMALONIC ACID 42 2

METHYLMALONIC ACID U 2 1

MISC-ARUP 1 1

MONTHLY ESTIMATE

(ROUNDED UP)

MISC-CHANTILLY 29 2

MISC-MAYO 6 1

MITOCHONDRIAL M2 42 2

MIXING STUDY 16 1

MOG AB TITER, SERUM 1 1

MOG AB W/RFL TITER,S 15 1

MOLD SUSCEPT,5 DRUGS 8 1

MORPHINE 49 2

MPL MUTATION 25 1

MSA AB PANEL 88 4

MTHFR, DNA MUTATION 3 1

MUMPS V AB(IGM) 4 1

MUMPS VIRUS IGG, EIA 14 1

MUSK QN AB TITER 81 3

MYCO, BLOOD CULTURE 1 1

MYCO/UREA CULT. 3 1

MYCOBACT SM CULT 50 2

MYCOPHENOLIC ACID, S 1 1

MYCOPLASMA PNEU.PCR 1 1

MYELIN IGG AB 2 1

MYELOPEROXIDASE AB 278 10

MYOGLOBIN 1 1

MYOGLOBULIN, URINE 66 3

N TELOPEPTIDE,SERUM 1 1

NICOTINE/COTININE SP 15 1

NICOTINE/COTININE U 5 1

NOROVIRUS RNA,RT PCR 5 1

NORTRIPTYLINE 3 1

NOTCH3 SEQ TEST 21 1

NUCLEOTIDASE, 5' 21 1

OLIGOCLONAL BANDING 8 1

ORG ACID COMP QUANT 2 1

OROTIC ACID, URINE 1 1

OSMOLALITY, FECES 2 1

OVA AND PARASITE 119 5

OXCARBAZEPINE 19 1

OXYCODONE QN 31 2

P-ANCA TITER 6 1

P190 BCR ABL1 44 2

P210 BCR ABL1 60 3

PARANEO AUTOAB EVAL 2 1

PARANEOPLASTIC IFA 20 1

PARVO B19 IGG/IGM 8 1

PDM TEST 01 208 8

PFAS (FOREVER CHEM)9 1 1

PHENYTOIN, FREE 11 1

PHOSPHATIDYLETHANOL 4 1

PLA2R AB, ELISA 6 1

PLA2R AB, IFA 20 1

PLATELET AB, DIRECT 3 1

PLATELET COUNT 3 1

PLT AB SCREEN SERUM 12 1

PNH W/FLAER (HS) 4 1

MONTHLY ESTIMATE

(ROUNDED UP)

PORPH FRAC, 24HR (U) 4 1

PORPHOBILINOGEN, 24HR (U) 5 1

PORPHOBILINOGEN, RAND (U) 6 1

PORPHYRINS, TOT (P) 8 1

PRA LC/MS/MS 169 7

PREGABALIN 7 1

PRIMIDONE 2 1

PROBNP 5 1

PROCAINAMIDE 3 1

PROCOLLAGEN TYPE I 2 1

PROGESTERONE 60 3

PROINSULIN 1 1

PROPAFENONE 1 1

PROTEIN C, ACTIVITY 82 3

PROTEIN C, ANTIGEN 28 1

PROTEIN ELECT W/REFL 634 23

PROTEIN ELECTRO, (U) 73 3

PROTEIN ELECTRO. 71 3

PROTEIN S ACT. ANT TOTAL 26 1

PROTEIN S AG, TOTAL 7 1

PROTEIN S, ACTIVITY 48 2

PROTEINASE-3 AB 277 10

PROTH. TIME MIX CORR 3 1

PROTHROMBIN GENE 71 3

PROTOPORPHYRIN, ZINC 3 1

PS/PT AB (IGG) 220 8

PS/PT AB (IGM) 220 8

PTH,INTACT & CALCIUM 29 2

PTH-RELATED PROTEIN 41 2

PTT MIX/CORR/INCUBAT 10 1

PTT, ACTIVATED 16 1

PTXPLNT,HBV,RT PCR,S 1 1

PYRUVATE (B) 51 2

Q FEV.IGG PHSI TITER 1 1

Q FEVER IGG PHSI SCR 2 1

Q FVR IGG PHS II SCR 2 1

Q FVR IGG PHSII TITR 1 1

Q FVR IGM PHSEI SCR 2 1

Q FVR IGM PHSII SCRN 2 1

QT THYROGLOB W/O ATA 91 4

QUANTIFERON(R) PL 4T 1 1

QUEST AD DETECT(TM), BETA 2 1

QUESTASSURED VIT D 1 1

QUETIAPINE;SP 1 1

RABIES VACCINE RESP 2 1

RAPAMYCIN-SIROLIMUS 19 1

RHEUMATOID FACTOR,SC 1 1

RISTOCETIN COFACTOR 16 1

RMSF IGG/IGM W/REFL 9 1

RNA POLYMERASE III 2 1

RPR MONITOR W/REFL 141 6

RPR TITER 77 3

RT3 BY LC/MS/MS 77 3

MONTHLY ESTIMATE

(ROUNDED UP)

RUBELLA IGM AB 18 1

RUBELLA IMMUNE 5 1

S.PNEUM IGG(14 SERO) 17 1

SALMONELLA AB EIA 2 1

SCHISTOSOMIASIS IGG 1 1

SCL-70 51 2

SELENIUM, B 6 1

SEROTONIN REL. ASSAY 12 1

SEROTONIN, SERUM 6 1

SHBG 348 13

SICKLE CELL SCREEN 4 1

SJOGREN'S ANTIBODIES 45 2

SJOGRENS AB (SS-B) 33 2

SM ANTIBODY 7 1

SM/RNP ABS 5 1

SMA 2+0 1 1

SMOOTH MUSC RFX/TIT 50 2

SMOOTH MUSCL TITER 3 1

SOLUBLE LIVER AG ABS 2 1

SS A RO AB(IGG)EIA 33 2

STONE ANALYSIS 65 3

STONE RISK DIAG PROF 39 2

STRIATED AB TITER 2 1

STRIATED MUSCLE W/REFL 20 1

STRONGYLOIDES IGG AB 1 1

SUS. YEAST COMP PNL 19 1

SUSCEPT AER MIC 8 1

SUSCEPT,PNL ANAEROBE 2 1

T CELL RECEPT TCR 1 1

T-3 UPTAKE 58 3

T-3, FREE 589 22

T-3, TOTAL 160 6

T-4 (THYROXINE) 80 3

T.VAGINALIS RNA,MALE 44 2

TACROLIMUS, LC/MS/MS 148 6

TCELL RECEPT GAMMA 2 1

TESTOSTERONE, FREE 1313 47

TESTOSTERONE,TOTALMS 315 12

TETANUS ANTITOXOID 3 1

THIOPURINE METAB 2 1

THROMBIN TIME 12 1

THROMBOPOIETIN (TPO) 2 1

THYROGLOBULIN AB 207 8

THYROID PEROXID AB 143 6

TOPIRAMATE 6 1

TOXO IGG AB 6 1

TOXO IGM EIA 6 1

TPMT GENOTYPE 1 1

TRAB 22 1

TRAMADOL AND METABOL 812 29

TRICHOMONAS VAG RNA, QL 33 2

TRYPTASE TOTAL 5 1

TSIG 51 2

MONTHLY ESTIMATE

(ROUNDED UP)

TTG IGA 62 3

TTG IGG 1 1

TUBEROUS SCLEROSIS 1 1

URORISK DIAG PROF 1 1

VALPROIC ACID, FREE 1 1

VDRL, CSF 9 1

VEDOZ QN AB 1 1

VGCC AB ASSAY 33 2

VGCC TYPE N AB 29 2

VGKC ANTIBODY 18 1

VIP 3 1

VISCOSITY 3 1

VITAMIN A (RETINOL) 30 2

VITAMIN B1,LCMSMS,P 139 5

VITAMIN B1,THIAMINE 1 1

VITAMIN B2 15 1

VITAMIN B3 9 1

VITAMIN B6 39 2

VITAMIN B7 (BIOTIN) 3 1

VITAMIN C 18 1

VITAMIN D,1,25 88 4

VITAMIN E 26 1

VITAMIN K, PLASMA 15 1

VLC FATTY ACIDS 3 1

VON WILLEBRAND AG 16 1

VON WILLEBRAND, MULT 6 1

VZV AB IGM 4 1

VZV DNA QN PCR 5 1

VZV IGG AB 9 1

WEST NILE VIRUS CSF 7 1

WEST NILE VIRUS,(S) 8 1

WHIPPLE'S DNA PCR 1 1

YEAST ID 20 1

YEAST ID AND SUSCEPT 20 1

YO AB SCR W/REFLEX 1 1

YO AB WB, SERUM 1 1

ZINC (P) 87 4

ZNT8 ANTIBODY 13 1

(END OF STATEMENT OF WORK)